Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment

• Status: Recruiting
• Trial end date: 2024-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will enroll CML patients who have failed a first TKI stopping attempt. After failure and at least a year of TKI treatment, patients will proceed to dasatinib treatment for another 2 years. If MR4 or better is re-achieved and maintained for at least one year, patients will be eligible for a second stop. After verification of MR4, TKI treatment will be stopped and patients followed in the same manner as after first stop. If MMR is lost (BCR-ABL >0.1% (IS)), TKI treatment will once again be restarted.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: VU University Medical Center
• Collaborators: Aarhus University Hospital; Helse Stavanger HF; Helsinki University Central Hospital; Henri Mondor University Hospital; Odense University Hospital; Skane University Hospital; St. Olavs Hospital; University Hospital, Bonn; Uppsala University Hospital
• Treatments: Dasatinib

Criteria

Inclusion Criteria:

1. CML in chronical phase (CP) under TKI treatment after failing a prior attempt to stop treatment within EURO-SKI or outside the study but according to EURO-SKI trial procedures. For the latter group this requires at least 3 years of TKI treatment (first line or second line due to intolerance to first line) before first stop, and MR4 for at least one year before stopping.

2. Treated with TKI for at least one year after having failed a prior attempt to stop TKI. Previous TKI can be any.

3. Typical BCR/ABL1 transcript (b3a2 and/or b2a2) must have been confirmed at diagnosis or later during the disease course.

4. 18 years or older.

Exclusion Criteria:

1. Previous hematological relapse after first stop of TKI.

2. Previous AP/BC at any time in the history of the disease.

3. Restart of TKI without loss of MMR after first stop

4. Current participation in another clinical study.

5. Previous or planned allogeneic stem cell transplantation.

6. Patients with contra-indications to dasatinib therapy due to comorbidities.

7. Subjects with acute hepatitis B virus (HBV) infections.

8. Uncontrolled or significant cardiovascular disease.

9. Pulmonary arterial hypertension.

10. Pleural or pericardial effusions of any grade at study entry are excluded

11. History of significant bleeding disorder unrelated to CML

12. Hypersensitivity to dasatinib and excipients of dasatinib tablets.